Veradermics, Incorporated (NYSE:MANE – Get Free Report) has earned an average recommendation of “Moderate Buy” from the eight brokerages that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $135.60.
MANE has been the subject of a number of research analyst reports. Wall Street Zen upgraded shares of Veradermics from a “sell” rating to a “hold” rating in a report on Sunday, June 14th. Weiss Ratings initiated coverage on shares of Veradermics in a research note on Tuesday, May 26th. They set a “sell (d+)” rating for the company. Citigroup upped their price objective on Veradermics from $120.00 to $135.00 and gave the company a “buy” rating in a research note on Monday, May 18th. Leerink Partners increased their price objective on Veradermics from $75.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, April 22nd. Finally, Lifesci Capital started coverage on Veradermics in a research report on Tuesday, June 16th. They issued an “outperform” rating and a $135.00 target price for the company.
Get Our Latest Stock Report on MANE
Veradermics Stock Performance
Veradermics (NYSE:MANE – Get Free Report) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.76).
About Veradermics
MANE is a global manufacturer and supplier of flavors, fragrances and ingredients for the food, beverage, personal care, household and fine fragrance markets. Headquartered in France, the company develops and produces aromatic solutions that are used by consumer goods companies, food processors, perfumers and formulators seeking sensory impact, taste modulation and olfactory character for their products.
The company’s product portfolio includes savory and sweet flavor systems, beverage concentrates, natural extracts, essential oils, fragrance compounds, cosmetic ingredients and specialty functional solutions such as taste enhancers and odor masking agents.
Featured Articles
- Five stocks we like better than Veradermics
- Apple and Broadcom Forge a Decade-Long Silicon Fortress
- SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
- The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
- Palantir’s CEO Just Called Out OpenAI and Anthropic
Receive News & Ratings for Veradermics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veradermics and related companies with MarketBeat.com's FREE daily email newsletter.
